Abstract
Merck & Co Inc is developing the cannabinoid receptor type 1 inverse agonist taranabant for the potential treatment of obesity and nicotine dependence. By October 2006, the drug had entered phase III trials for obesity, and by May 2008, a phase II study of taranabant as an aid to smoking cessation in chronic cigarette smokers had been completed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1116-1129 |
| Number of pages | 14 |
| Journal | Current Opinion in Investigational Drugs |
| Volume | 9 |
| Issue number | 10 |
| State | Published - 2008 |
ASJC Scopus subject areas
- Pharmacology
- Drug Discovery